FDA Approves Moderna’s mRNA-Based Flu Vaccine for Adults 50 and Older
The U.S. Food and Drug Administration (FDA) has approved Moderna's new mRNA-based seasonal flu vaccine, named mFLUSIVA. This vaccine will be available for individuals aged 50 and older starting with the 2026-2027 respiratory illness season.
San Francisco Oakland San Jose, CA, August 6, 2026 —
The U.S. Food and Drug Administration (FDA) has granted approval for Moderna’s new mRNA-based seasonal influenza vaccine, to be marketed as mFLUSIVA. This marks a significant development in the availability of new vaccine technologies for respiratory illnesses.
According to the approval, mFLUSIVA is indicated for use in individuals aged 50 years and older. The vaccine is slated to become available for the upcoming 2026-2027 respiratory illness season.
Moderna’s mFLUSIVA utilizes messenger RNA (mRNA) technology, similar to the platform used for some COVID-19 vaccines. This approach aims to elicit an immune response against influenza viruses.
The FDA’s decision follows a review process evaluating the safety and efficacy of the vaccine for the specified age group. Further details regarding the clinical trial data and specific flu strains targeted by mFLUSIVA were not immediately available.
This approval represents a step forward in diversifying the types of vaccines available for seasonal flu prevention, particularly for older adults who are often at higher risk for complications from influenza. The 2026-2027 respiratory illness season will be the first period during which mFLUSIVA will be offered to the public.
Story summarized from the original created by KGO-TVWebTeam@email.disney.com(KGO-TV San Francisco) on abc7news.com, see more information here.
